Peptide News Digest

#Chugai

2 stories

Clinical Trials · View digest

Roche Ends Obesity Development of Emugrobart, a Muscle-Preserving Anti-Myostatin Antibody, After Phase 2 GYMINDA Interim Analysis

Chugai announced on Monday, September 28, 2026 that Roche is discontinuing development of emugrobart (GYM329), a subcutaneous anti-latent myostatin antibody, for obesity after an interim analysis of the Phase 2 GYMINDA study concluded that the trial was unlikely to meet its pre-specified weight-loss objectives. GYMINDA tested emugrobart in combination with GLP-1/GIP receptor agonists in people with obesity or overweight; Chugai said the antibody was well tolerated, with no new safety signals. All rights return to Chugai, which is preparing to resume development in spinal muscular atrophy and considering out-licensing; Roche had already stopped emugrobart development in spinal muscular atrophy and facioscapulohumeral muscular dystrophy in March 2026.

Research · View digest

TIDES USA Day 1: Chugai LUNA18 Kilogram-Scale GMP Production Paper — Oral Cyclic Peptide KRAS Inhibitor Cleared Through 24-Step Liquid-Phase Synthesis

TIDES USA 2026 opens in Boston May 11-14 with a featured presentation on Chugai's LUNA18 (paluratide), an N-alkyl-rich cyclic undecapeptide oral KRAS inhibitor. The corresponding paper in Organic Process Research & Development describes a convergent 24-step liquid-phase synthesis route delivering kilogram-scale GMP material at >98.5% purity and >30% overall yield. LUNA18 binds KRAS, NRAS, and HRAS mutants plus wildtype, inhibiting the inactive-state RAS-GEF protein-protein interaction; it achieves 21-47% oral bioavailability without special formulation. The molecule is in Phase 1 monotherapy and combination-with-cetuximab dose escalation. LUNA18's chemistry is a milestone for the oral-cyclic-peptide-against-intracellular-targets thesis that Bicycle Therapeutics, Circle Pharma, and Unnatural Products are advancing through different platform architectures.